Lamivudine

Lamivudine (CAS 134678-17-4), also known by the abbreviation 3TC and supplied under the trade name Heptovir, is a nucleoside reverse transcriptase inhibitor used as an active pharmaceutical ingredient.

It is a core component in formulations targeting HIV and chronic hepatitis B, and is recognized globally as an essential API in both branded and generic pharmaceutical pipelines for global distribution.

Lamivudine is primarily used in the manufacture of oral solid dosage forms, such as tablets and film-coated tablets, for HIV treatment regimens often combined with other antiretroviral APIs in products.

Generic pharmaceutical manufacturers source it as a key API for hepatitis B antiviral therapies, where regulatory-grade purity is a critical procurement requirement for international safety standards.

It is also used by formulators developing pediatric oral solutions, requiring specific solubility-compatible grades. Contract development and manufacturing organizations source it as a synthesis intermediate.

Lamivudine is available as a white crystalline powder in pharmaceutical-grade specifications. Recognized grades include USP, BP, and Ph. Eur., aligning with the requirements of regulated markets.

These standards ensure compliance in North America, Europe, and beyond. Supply is typically offered in kilogram to metric-ton quantities, with documentation packages supporting GMP-compliant procurement.